Goldman Sachs Group started coverage on shares of Repare Therapeutics (NASDAQ:PAND) in a research note released on Tuesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $28.00 target price on the stock.
Separately, BMO Capital Markets began coverage on shares of Repare Therapeutics in a research note on Monday. They issued an outperform rating and a $29.00 target price for the company.
Shares of Repare Therapeutics stock traded up $0.27 during trading on Tuesday, reaching $18.83. 516 shares of the company traded hands, compared to its average volume of 177,296. Repare Therapeutics has a 1-year low of $16.67 and a 1-year high of $27.75.
Repare Therapeutics Company Profile
Pandion Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.